Wee1 Inhibitor ZN-c3 for Carcinoma, Ovarian Epithelial

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
OHSU Knight Cancer Institute, Portland, OR
Carcinoma, Ovarian Epithelial+18 More
Wee1 Inhibitor ZN-c3 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced). ZN-c3 is an enzyme inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Eligible Conditions

  • Carcinoma, Ovarian Epithelial
  • Stage IV Ovarian Cancer AJCC v8
  • Metastatic Triple-Negative Breast Carcinoma
  • Stage IV Primary Peritoneal Cancer AJCC v8
  • Advance Directives
  • Fallopian Tube Carcinoma
  • Advanced Ovarian Carcinoma
  • Stage III Ovarian Cancer AJCC v8
  • Breast
  • Advanced Primary Peritoneal Carcinoma
  • Stage III Primary Peritoneal Cancer AJCC v8

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Carcinoma, Ovarian Epithelial

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Day 1 to 30 days after last dose of study intervention

Day 21
Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells
ZN-c3 tumor and plasma concentrations
Year 1
Cellular and molecular characteristics
Day 30
Incidence of adverse events
Year 1
Progression free survival
Year 1
Time to disease progression
Year 1
Overall survival
Month 12
CBR for ovarian cancer
Clinical benefit rate (CBR)

Trial Safety

Safety Progress

1 of 3

Other trials for Carcinoma, Ovarian Epithelial

Trial Design

1 Treatment Group

Treatment (wee1 inhibitor ZN-c3)
1 of 1
Experimental Treatment

14 Total Participants · 1 Treatment Group

Primary Treatment: Wee1 Inhibitor ZN-c3 · No Placebo Group · Phase < 1

Treatment (wee1 inhibitor ZN-c3)
Drug
Experimental Group · 1 Intervention: Wee1 Inhibitor ZN-c3 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 to 30 days after last dose of study intervention
Closest Location: OHSU Knight Cancer Institute · Portland, OR
Photo of Portland 1Photo of Portland 2Photo of Portland 3
2003First Recorded Clinical Trial
3 TrialsResearching Carcinoma, Ovarian Epithelial
104 CompletedClinical Trials

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER
880 Previous Clinical Trials
6,828,315 Total Patients Enrolled
1 Trials studying Carcinoma, Ovarian Epithelial
131 Patients Enrolled for Carcinoma, Ovarian Epithelial
OHSU Knight Cancer InstituteLead Sponsor
206 Previous Clinical Trials
2,090,828 Total Patients Enrolled
2 Trials studying Carcinoma, Ovarian Epithelial
131 Patients Enrolled for Carcinoma, Ovarian Epithelial
Zahi Mitri, MD, MSPrincipal InvestigatorOHSU Knight Cancer Institute
4 Previous Clinical Trials
200 Total Patients Enrolled
Evthokia Hobbs, M.D.Principal InvestigatorOHSU Knight Cancer Institute

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a low estrogen and progesterone receptor.
You have received prior treatment related toxicities.
You must provide written informed consent before any study-specific procedures or interventions are performed.
HER2 amplification by CAP guidelines.
You have biopsy proven advanced ovarian cancer.
You have a measurable site of disease as defined by RECIST version (v) 1.1 that is amendable to biopsy.
You have received at least one standard of care line of therapy in the recurrent setting.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.